Literature DB >> 20802520

Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas.

N E Savaskan1, S Seufert, J Hauke, C Tränkle, I Y Eyüpoglu, E Hahnen.   

Abstract

Malignant glioma represents one of the most aggressive and lethal human neoplasias. A hallmark of gliomas is their rapid proliferation and destruction of vital brain tissue, a process in which excessive glutamate release by glioma cells takes center stage. Pharmacologic antagonism with glutamate signaling through ionotropic glutamate receptors attenuates glioma progression in vivo, indicating that glutamate release by glioma cells is a prerequisite for rapid glioma growth. Glutamate has been suggested to promote glioma cell proliferation in an autocrine or paracrine manner, in particular by activation of the (RS)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid hydrate (AMPA) subtype of glutamate receptors. Here, we dissect the effects of glutamate secretion on glioma progression. Glioma cells release glutamate through the amino-acid antiporter system X(c)(-), a process that is mechanistically linked with cystine incorporation. We show that disrupting glutamate secretion by interfering with the system X(c)(-) activity attenuates glioma cell proliferation solely cystine dependently, whereas glutamate itself does not augment glioma cell growth in vitro. Neither AMPA receptor agonism nor antagonism affects glioma growth in vitro. On a molecular level, AMPA insensitivity is concordant with a pronounced transcriptional downregulation of AMPA receptor subunits or overexpression of the fully edited GluR2 subunit, both of which block receptor activity. Strikingly, AMPA receptor inhibition in tumor-implanted brain slices resulted in markedly reduced tumor progression associated with alleviated neuronal cell death, suggesting that the ability of glutamate to promote glioma progression strictly requires the tumor microenvironment. Concerning a potential pharmacotherapy, targeting system X(c)(-) activity disrupts two major pathophysiological properties of glioma cells, that is, the induction of excitotoxic neuronal cell death and incorporation of cystine required for rapid proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802520     DOI: 10.1038/onc.2010.391

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis.

Authors:  A Ghoochani; M A Schwarz; E Yakubov; T Engelhorn; A Doerfler; M Buchfelder; R Bucala; N E Savaskan; I Y Eyüpoglu
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

2.  Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma.

Authors:  Rita Sattler; Betty Tyler; Benjamin Hoover; Luke T Coddington; Violette Recinos; Lee Hwang; Henry Brem; Jeffrey D Rothstein
Journal:  J Neurosurg       Date:  2013-08-02       Impact factor: 5.115

Review 3.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

Review 4.  Surgical resection of malignant gliomas-role in optimizing patient outcome.

Authors:  Ilker Y Eyüpoglu; Michael Buchfelder; Nic E Savaskan
Journal:  Nat Rev Neurol       Date:  2013-01-29       Impact factor: 42.937

5.  Activation of NMDA receptor of glutamate influences MMP-2 activity and proliferation of glioma cells.

Authors:  Palaniswamy Ramaswamy; N Aditi Devi; K Hurmath Fathima; Nandakumar Dalavaikodihalli Nanjaiah
Journal:  Neurol Sci       Date:  2013-12-29       Impact factor: 3.307

6.  Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.

Authors:  Gökçe Hatipoglu; Stefan W Hock; Ruth Weiss; Zheng Fan; Tina Sehm; Ali Ghoochani; Michael Buchfelder; Nicolai E Savaskan; Ilker Y Eyüpoglu
Journal:  Cancer Sci       Date:  2015-02-15       Impact factor: 6.716

7.  Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy.

Authors:  Jan Lewerenz; Paul Baxter; Rebecca Kassubek; Philipp Albrecht; Joeri Van Liefferinge; Mike-Andrew Westhoff; Marc-Eric Halatsch; Georg Karpel-Massler; Paul J Meakin; John D Hayes; Eleonora Aronica; Ilse Smolders; Albert C Ludolph; Axel Methner; Marcus Conrad; Ann Massie; Giles E Hardingham; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

Review 8.  Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy.

Authors:  Falko Lange; Julia Hörnschemeyer; Timo Kirschstein
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

9.  Neurodegeneration and the Brain Tumor Microenvironment. [corrected].

Authors:  Nicolai E Savaskan; Zheng Fan; Thomas Broggini; Michael Buchfelder; Ilker Y Eyüpoglu
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 10.  Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Int J Biol Sci       Date:  2013-08-09       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.